Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
Trial Parameters
Brief Summary
During the last fifteen years, the landscape of AML diagnosis and therapeutical options has markedly evolved. Refined genetic and prognostic characterizations, together with new drug approvals and new allogeneic hematopoietic stem cell transplantation (HSCT) procedures, have increased patient journey diversity.
Eligibility Criteria
Inclusion Criteria: * Patient aged 18 years old or more * Patient with newly diagnosed previously untreated de novo, secondary or therapy-related AML * Patients with R/R de novo, secondary or therapy-related AML * Patient with Health insurance Exclusion Criteria: * Acute promyelocytic leukemia * AML which is not morphologically proven (patients with granulocytic sarcoma may be included) * For newly diagnosed AML: previous treatment of leukemia apart from hydroxyurea. Previous anti leukemia treatments are allowed if they were administered before the diagnosis of AML to treat a MDS, MPN, MPN/MDS or CML * Patient weighting less than 50 kgs * Opposition of the patient to participate to this non-interventional study More specific eligibility criteria might be requested to enter some study modules